The RPMI 8226 cell line is derived from multiple myeloma and myelodysplastic syndrome, which responds to some myeloma treatments, exhibits high GCN2 expressions in the Oncomine database. This evidence concerns the gene EIF2AK4 and plasma cell myeloma.